Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | NAAA | Q02083 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | PRKCA | P17252 | 3/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | RAD52 | P43351 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19367024 | 1.00 | TSHR (0.46) | TSHRNAAACES2EPHX1ALDH1A1 | |
| SCHEMBL20261666 | 0.86 | ALDH1A1 (0.33) | TSHRALDH1A1HCAR2LMNA | |
| SCHEMBL19546111 | 0.85 | PAOX (0.36) | TSHRNAAALMNA | |
| SCHEMBL28179059 | 0.85 | NAAA (0.44) | TSHRNAAACES2EPHX1ALDH1A1 | |
| SCHEMBL18679881 | 0.85 | TSHR (0.37) | TSHRNAAACES2EPHX1ALDH1A1 | |
| SCHEMBL12731629 | 0.84 | TSHR (0.41) | TSHRNAAACES2EPHX1ALDH1A1 | |
| SCHEMBL11158310 | 0.83 | TSHR (0.49) | TSHRNAAACES2EPHX1ALDH1A1 | |
| SCHEMBL14967788 | 0.83 | TSHR (0.49) | TSHRNAAACES2EPHX1ALDH1A1 | |
| SCHEMBL1537680 | 0.83 | PRKCA (0.47) | TSHRNAAAEPHX1PRKCA | |
| SCHEMBL13539366 | 0.83 | PRKCA (0.47) | TSHRNAAAEPHX1PRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170087167-A1 | MODIFICATION OF DRUGS FOR INCORPORATION INTO NANOPARTICLES | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2017-03-30 | — | — | US | disclosed |
| US-20170087167-A1 | MODIFICATION OF DRUGS FOR INCORPORATION INTO NANOPARTICLES | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2017-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170087167-A1 | MODIFICATION OF DRUGS FOR INCORPORATION INTO NANOPARTICLES | NLN, PRNP, TPMT | TSHR 4627/4885NAAA 110/4885CES2 346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.